IL21

(redirected from Interleukin 21)
Also found in: Wikipedia.

IL21

A gene on chromosome 4q26-q27 that encodes IL-21, a cytokine with immunoregulatory activity that may promote the transition between innate and adaptive immunity. IL21 induces the production of IgG1 and IgG3 in B cells, and may play a role in proliferation and maturation of natural killer cells in synergy with IL15. It is also a less preferred gene symbol for what is now designated as IL17C (see there), as well as IL22 (see there).
References in periodicals archive ?
Interleukin 21 (IL-21) has a pleiotropic effect on inflammation regulation.
30 September 2010 - US-based biopharmaceutical company ZymoGenetics Inc (NASDAQ: ZGEN) yesterday announced positive survival data from a Phase IIa clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent.
IRF-4-binding protein inhibits interleukin 17 and interleukin 21 production by controlling the activity of IRF-4 transcription factor.
NASDAQ:ZGEN) today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent.
NASDAQ:ZGEN) today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent.
The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.
NASDAQ:ZGEN) today announced positive final results from a Phase 2 clinical trial in patients receiving 2nd or 3rd line therapy for advanced renal cell carcinoma with the combination of recombinant Interleukin 21 (IL-21) and Nexavar([R])(sorafenib) tablets.
The clinical trial evaluated Interleukin 21 (IL-21) in combination with Nexavar([R])(sorafenib) tablets.
NASDAQ:ZGEN) today announced that Interleukin 21 (IL-21) demonstrated an impressive overall response rate in the treatment of metastatic melanoma.
NASDAQ: ZGEN) announced today the acquisition of ex-North American rights to Interleukin 21 (IL-21) from Novo Nordisk A/S, resulting in ZymoGenetics owning worldwide rights to IL-21.
NASDAQ: ZGEN) presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar([R]) (sorafenib) tablets in patients with metastatic renal cell cancer.
NASDAQ:ZGEN) today announced that results from Interleukin 21 (IL-21) studies will be presented or published at the American Society of Clinical Oncology (ASCO) 2008 annual meeting.